Greeve J, Philipsen A, Krause K, et al. Expression of activation-in-duced cytidine deaminase in human B-cell non-Hodgkin lymphomas[J]. Blood, 2003, 101(9): 3574-3580.
[2]
Hans C P. Weisenburger DD,Greiner TC , et al. Confirmation of the mo-lecular classification of diffuse large B-cell lymphoma by immunohis-tochemistry using a tissue microarray [J]. 2004, 103(1): 275-282.
[3]
Matsumoto Y, Marusawa H, Kinoshita K, et al. Helicobacter pylori in-fection triggers aberrant expression of activation- induced cytidine de-aminasein gastric epithelium [J]. NatMed, 2007, 13（4）: 470-476.
[4]
Seki R, Ohshima K, Fujisaki T, et al. Prognostic impact of immunohis-tochemical biomarkers in diffuse large B-cell lymphoma in the ritux-imab era [J]. Cancer Sci, 2009, 100(100): 1842-1847.
[5]
Choi WW, Weisenburger DD, Greiner TC, et al. A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy [J]. Clin Cancer Res, 2009, 15(17):
[6]
5494-5502.
[7]
Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large Bcell lymphoma treated with rituximab [J]. J Clin Oncol, 2011, 29 (2):200-207.
[8]
Morton LM, Cerhan JR, Hartge P, et al. Immunostaining to identify mo-lecular subtypes of diffuse large B-cell lymphoma in a populationbased epidemiologic study in the pre-rituximab era [J]. Int J Mol Epi-demiol Genet, 2011, 2 (3): 245-252.
[9]
Gutiérrez-García G, Cardesa-Salzmann T, Climent F,et al. Gene-ex-pression profiling and not immunophenotypic algorithms predicts prog-nosis in patients with diffuse large B-cell lymphoma treated with im-munochemotherapy [J]. Blood, 2011, 117 (18): 4836-4843.
[10]
Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rear-rangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunopheno- type and poor outcome [J]. Modern Pathology, 2012, 25(1):145-156.
[11]
Liu M, Duke JL,Richter DJ,et al. Two levels of protection for the B cell genome during somatic hypermutation [J]. Nature, 2008, 451 （7180）: 841-845.
[12]
Kim JH, Kim WS, Park C. Epstein-Barr virus latent membrane pro-tein 1 increases genomic instability through Egr-1-mediated up-reg-ulation of activation-induced cytidine deaminase in B-cell lymphoma [J]. Leuk Lymphoma,2013, 54(9): 2035-2040.
[13]
Leuenberger M, Frigerio S, Wild PJ, et al. AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma isas-sociated with poor prognosis and complex genetic alterations [J]. Mod Pathol. 2010, 23(2):177-186.
Aguilera NS, Auerbach A, Barekman CL, et al.Activation-induced cy-tidine deaminase expression in diffuse large B- cell lymphoma with aparacortical growth pattern: a lymphoma of possible interfollicu-lar large B-cell origin [J]. Arch Pathol Lab Med, 2010, 134 (3): 449-456.
[16]
Lossos IS, Levy R, Alizadeh AA. AID is expressed in germinal cen-ter B-cell-like and activated B-cell-like diffuse large-cell lympho-mas and is not correlated with intraclonal heterogeneity [J].Leukemia,2004, 8 (11): 1775-1779.
